Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022:2547:47-61.
doi: 10.1007/978-1-0716-2573-6_3.

Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer

Zahra Talebi  1 , Alex Sparreboom  2 , Susan I Colace  3   4
Affiliations
Review

Pharmacogenomics in Targeted Therapy and Supportive Care Therapies for Cancer

Zahra Talebi et al. Methods Mol Biol. 2022.

Abstract

Targeted therapies have significantly altered the landscape of available cancer therapies across all diagnoses and patient populations, and supportive care therapies have steadily improved throughout the years to make therapy more tolerable for patients. Even so, these therapies have varied efficacy and toxicity among patients with cancer, and pharmacogenomics presents an opportunity to identify which patients are most at risk of toxicities and most likely to benefit from them. While the field of pharmacogenomics in targeted cancer therapy is still growing, we review current knowledge, hypotheses, and clinical practices in this chapter, along with a brief review of pharmacogenomics in supportive therapies in cancer treatment.

Keywords: Cancer; Chemotherapy; Efficacy; Pharmacogenomics; Targeted therapies; Toxicity.

PubMed Disclaimer

References

    1. Talebi Z, Baker SD, Sparreboom A (2023) Pharmacology of small-molecule anticancer agents. In: Bast RC Jr, Byrd J, Croce CM(eds) Holland-Frei cancer medicine, 10th edn. Wiley Blackwell, USA
    1. Schneider BP, Wang M, Radovich M et al (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26(28):4672–4678 - DOI - PubMed - PMC
    1. Udagawa C, Zembutsu H (2020) Pharmacogenetics for severe adverse drug reactions induced by molecular-targeted therapy. Cancer Sci 111(10):3445–3457 - DOI - PubMed - PMC
    1. Diasio RB, Innocenti F, Offer SM (2021) Pharmacogenomic-guided therapy in colorectal cancer. Clin Pharmacol Ther 110(3):616–625 - DOI - PubMed
    1. Dulucq S, Bouchet S, Turcq B et al (2008) Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 112(5):2024–2027 - DOI - PubMed

Substances

LinkOut - more resources